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ABSTRACT 
Objective: In the present study, transdermal nanoemulsion (NE) gel of lovastatin was investigated for its anti-osteoporosis effect on the long bones 
of rat i.e. tibia.  
Methods: Male wistar rats (n=30, weighing 180-200g) were taken for this study and grouped as: 1) control (normal saline daily), 2) Dex 
(dexamethasone sodium; 25 mg/kg subcutaneously twice a week), 3) Dex+LNG5 (lovastatin nanoemulsion gel; 5 mg/kg/d transdermally daily), 4) 
Dex+LNG10 (lovastatin nanoemulsion gel; 10 mg/kg/d transdermally daily), and 5) Dex+ALN (alendronate sodium; 0.03 mg/kg/d orally daily). All 
the treatments were carried out for 60 d. At the end of the experiment, all animals were anesthetized using diethyl ether and collected blood 
samples from retro-orbital venous plexus of rats in dry eppendorf tubes followed by the sacrifice of animals by cervical dislocation method and 
collected tibia bones of both the legs for analysis.  
Results: Bone formation biomarkers (OC: osteocalcin, b-ALP: bone-specific alkaline phosphatase, PINP: N-terminal propeptides of type I procollagen) 
were significantly improved and resorption biomarkers (CTx: C-terminal cross-linking telopeptides of type-I collagen, TRAcP5b: isoform 5b of tartarate 
resistant acid phosphatase) were significantly reduced in the LNG5 (p<0.05) and LNG10 (p<0.05) treatment groups when compared to Dex. In vivo anti-
osteoporotic results demonstrated the formation of new bone in osteoporotic rat tibias. Biomechanical strength testing demonstrated increased load-
bearing capacity of rat tibias in the treated animals in comparison with the osteoporotic group (p<0.05 for LNG5 and p<0.01 for LNG10).  
Conclusion: Thus, the transdermal NE gel formulation of lovastatin demonstrated the greater potential for the treatment of osteoporosis. 
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Osteoporosis is a highly prevalent metabolic bone disorder 
characterized by low bone mineral density and deteriorated 
microarchitecture of bone [1]. It often results in hip, distal arm and 
spine fractures. The increased risk of fragility fractures in osteoporosis 
poses a threat to life expectancy and quality of life in both men and 
women. With advancing age, bone resorption increases in comparison 
to bone formation, which causes deterioration of bone and thus leads 
to osteoporosis. Osteoporosis is of two types, primary and secondary. 
Glucocorticoid (GC) induced osteoporosis is the most common form of 
secondary osteoporosis [2]. GC induces apoptosis of both osteoblasts 
and osteoclasts but increases the resorption process by increasing the 
life span of pre-existing osteoclasts [3].  
There are various mechanisms by which GCs induce osteoporosis viz. 
they suppress osteoblasts function which reduces bone remodeling and 
impairs bone tissue repair [4], inhibits the production of bone matrix 
components, reduces intestinal calcium absorption and increases renal 
calcium excretion leading to negative calcium balance [5]. GC’s inhibit the 
osteoanabolic action of sex steroids and causes secondary 
hyperparathyroidism [6]. Food and drug administration (FDA) has 
approved various drugs for the treatment of osteoporosis viz. 
bisphosphonates (alendronate, risedronate, zoledronate) and 
recombinant parathyroid hormone [7, 8]. But all of them suffer from 
serious drawbacks. However, utilization of statins as anabolic agents [9, 
10] in osteoporosis has spurred various experimental investigations. 
Statins are the low molecular weight 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitor which shows the anabolic effect on 
osteoporotic bones through various mechanisms viz. promoting 
osteogenesis, suppressing apoptosis of osteoblasts and inhibiting 
osteoclastogenesis [11, 12]. Statins suffer from the major limitation 
of the first-pass metabolism in the liver, which reduces their 
systemic availability to 2-4% approximately. The low concentrations 
of statins are not sufficient to reach bone tissue and produce 
osteogenic effects [13]. Thus local drug delivery systems need to be 
investigated to increase the concentration of statins reaching bone 
effectively. There are the number of approaches utilised by various 
researchers viz. multiple injections at single site [14, 15], implants 
[16, 17], scaffolds [18, 19], hydrogels [20, 21] etc. These approaches 
have provided significant results in improving osteoporosis but their 
major limitation is being invasive. Patient compliance is not taken 
care in these approaches. Transdermal nanoemulsion gel has shown 
quite significant improvement in osteoporosis [22, 23] and is the 
completely non-invasive approach.  
In the present study; effect of transdermal nanoemulsion gel was 
studied. The aim of this investigation was to study the anti-
osteoporotic effect of transdermal lovastatin NE gel in the long 
bones i.e. tibia using glucocorticoid-induced osteoporosis rat model. 
MATERIALS AND METHODS 
Chemicals and reagents 
Lovastatin was obtained as a gift sample from Panacea Biotec, New 
Delhi. Labrafac PG and transcutol P were obtained as a gift sample 
from Gattefosse. Tween 80, diethyl ether, isopropyl alcohol, 
triethanolamine, phosphoric acid, sodium chloride and carbopol 940 
was procured from SD fine chemicals. Water was obtained from 
Milli-Q water purification system. Biochemical kits specific for 
alkaline phosphatase (ALP), calcium, phosphorus, total protein (TP), 
serum glutamate oxaloacetate transaminase (SGOT), serum 
glutamate pyruvate transaminase (SGPT), triglyceride and total 
cholesterol were procured from Accurex, Mumbai, India. OC, b-ALP, 
PINP, CTx, TRAcP5b rat specific ELISA kits were procured from 
Shanghai YL Biotech Co. Ltd., China. 
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Thirty male albino wistar rats, three months of age and weighing 
approximately 180-200 g were procured from Sanzyme Ltd., 
Hyderabad. Animals were maintained under controlled conditions of 
20 °C-25 °C temperature, 55-60% humidity, 12h light/dark cycle and 
fed on standard chow diet and water ad libitum. Their weights were 
recorded both before and after end of the study. The study design 
was approved by the Institutional Animal Ethics Committee 
(009/MRIPS/CPCSEA-IAEC/Hyd/2016).  
Preparation of lovastatin loaded NE gel 
The NE was prepared using aqueous phase titration method. Firstly, 
lovastatin (5 mg/ml) was added to 5% v/v of labrafac PG and shaken 
continuously till a clear solution is obtained. To this solution, 30% 
v/v of tween 80 and 30% v/v of transcutol was added. The mixture 
was vortexed for 1-2 min. Then finally 35% v/v of water was added 
and the mixture was shaken vigorously to obtain a clear, 
homogenous and transparent mixture. This results in the 
preparation of lovastatin loaded NE. In order to prepare NE gel, 
carbopol 940 polymer (1g) was firstly dissolved in 100 ml of water 
and allowed to swell for 24 h in dark place. To the swelled polymer, 
10 g each of propylene glycol and isopropyl alcohol were added and 
mixed continuously for 10-15 min., followed by addition of 0.5 g of 
triethanolamine which resulted in the formation of clear translucent 
gel [14, 24]. Finally, lovastatin loaded NE was mixed with 1g of 
above-prepared gel to result in the formation of lovastatin loaded NE 
gel (LNG5). Similarly, LNG10 was prepared wherein 10 mg/ml of 
lovastatin was added to 5% v/v of labrafac PG and prepared 
formulation henceforth. 
Experimental design 
One group of animals (n=6) received subcutaneous injection of normal 
saline (1 ml/kg/d) for 60 d. This group served as control. The second 
group (n=24) received dexamethasone sodium (Dex) (25 mg/kg) 
subcutaneously twice a week for 60 d to induce osteoporosis. Blood 
samples were collected from both the group of animals after 30 and 60 
d to analyse the levels of bone turnover markers and confirm 
osteoporosis induction. Treatments were started after induction of 
osteoporosis. The second group animals were further divided into 
treatment groups. The third group was administered lovastatin 
nanoemulsion gel (Dex+LNG5; 5 mg/kg/d) transdermally daily, fourth 
group received lovastatin nanoemulsion gel (Dex+LNG10; 10 
mg/kg/d) transdermally daily, and fifth group received alendronate 
sodium (Dex+ALN; 0.03 mg/kg/d) orally daily for 60 d.  
At the end of the experiment, all animals were anesthetized using 
diethyl ether and blood samples were collected from retro-orbital 
venous plexus of rats in dry eppendorf tubes. Blood samples were 
allowed to clot, centrifuged at 3000 rpm for 15 min and serum 
separated was collected and stored at -20 °C until further analysis. 
Immediately after this, animals were sacrificed by cervical 
dislocation method and collected tibia bones of both the legs. Tibia 
bones were weighed, rinsed with phosphate buffer saline (PBS) and 
stored at -20 °C after wrapping in gauze soaked with PBS until 
further investigation [25]. 
Biochemical assay  
The serum samples stored at -20 °C were thawed at room 
temperature first and analysed for albumin, alkaline phosphatase 
(ALP), calcium, cholesterol, creatinine, glucose, phosphorus, serum 
glutamate oxaloacetate transaminase (SGOT), serum glutamate 
pyruvate transaminase (SGPT), triglyceride and total protein. The 
samples were analyzed using fully automatic autoanalyzer (Accurex, 
Sphera autoanalyzer, Mumbai, India) [26]. 
Bone turnover marker assay 
Stored serum samples were first thawed at room temperature and 
used for evaluation of various bone turnover markers such as bone 
formation markers (OC: osteocalcin, b-ALP: bone-specific alkaline 
phosphatase, PINP: N-terminal propeptides of type I procollagen) 
and bone resorption markers (CTx: C-terminal cross-linking 
telopeptides of type-I collagen, TRAcP5b: isoform 5b of tartarate 
resistant acid phosphatase). These markers were analysed using 
commercially available rat specific ELISA kits [26].  
Micro-CT evaluation 
The stored tibia bones were thawed at room temperature before 
subjecting to Micro-CT analysis. During scanning, all tibia bones were 
wrapped in gauze soaked with phosphate buffer to prevent dehydration 
and scanned using X-radia versa XRM 500 Micro-CT scanner (X-radia, 
Zeiss, Germany). The radiographs were obtained longitudinally at 
proximal distal region of tibia. The parameters were set at 80 kV voltage, 
7.0 W power and 86.7 µA current with an exposure time of 10 sec, and 
voxel resolution of 13 µm. Tomographic image reconstruction was 
performed using XM reconstructor and XM3D viewer. The proximal-
distal cancellous bone microarchitecture was quantified for bone 
mineral density (BMD, g/cm3), bone volume to tissue volume ratio 
(BV/TV, %), trabecular bone thickness (TbTh, mm), trabecular number 
(Tb. N, 1/mm) and trabecular separation (Tb. Sp, mm) [27]. 
Biomechanical bone strength testing 
The biomechanical strength testing was performed on the compact bone 
using three-point bending test utilising 25 kN Universal testing machine 
(BiSS Makron, Bangalore, India). All the bone samples were thawed at 
room temperature before testing. For the test, the length of the bone 
samples was measured using vernier calliper. Tibia was placed 
horizontally on two supporting bars located at a span distance of 14 mm 
and third bar carefully positioned perpendicularly at the mid-axis of tibia 
bone (fig. 1). Load was applied at a displacement rate of 1 mm/sec until 
the bone fractures. The load-displacement curves were recorded (fig. 2) 
and calculated stiffness (N/mm), peak load (N), ultimate strength (mPa) 
and Young’s modulus (GPa) from the curve [28, 29]. All data were 
represented as mean±SD. 
 
 
Fig. 1: Representation of three-point bending test. 
 
Statistical analysis 
Data is represented as mean±SD. For comparing different treatment 
groups, one-way analysis of variance (ANOVA) was utilized, followed 
by Tukey’s multiple comparison test using Graph Pad Prism 5 
software (version 5.0). p<0.05 was considered significant. 
RESULTS  
Biochemical assay 
Serum albumin, ALP, calcium, cholesterol, creatinine, glucose, 
phosphorus, SGOT, SGPT, triglyceride, and total protein levels are 
represented in table 1. After induction of osteoporosis, serum ALP levels 
were significantly elevated in comparison with the control rats. 
Induction of osteoporosis using dexamethasone reduced the calcium and 
phosphorus levels as indicated in table 1 and significant improvements 
were observed in their levels after 60 d of treatment with LNG5 
(containing a low dose of lovastatin) and LNG10 (containing a high dose 
of lovastatin). The results were also comparable with the standard 
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treatment group ALN, thus hinting at the effectiveness of the prepared formulations of lovastatin in osteoporosis treatment. 
 
 
Fig. 2: Load (stress) displacement (strain) curve recorded from the three-point bending test. 
 
 
Fig. 3: Comparison of biomarker levels (a) BALP: bone-specific alkaline phosphatase, (b) OC: osteocalcin, (c) PINP: N-terminal 
propeptides of type I procollagen, (d) CTx: C-terminal cross-linking telopeptides of type-I collagen, (e) TRAcP5b: isoform 5b of tartrate 
resistant acid phosphatase in rat blood serum of various treated groups. *p<0.05, and **p<0.01 (ANOVA followed by Tukey’s multiple 
comparison test). 
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Table 1: Biochemical parameters analysed in blood sera of rats (n=6) 
 Control Dex Dex+LNG 5 Dex+LNG 10 Dex+ALN 
Alb (mg/dl) 3.59±1.9 2.35±0.98b 2.97±1.23 3.23±1.11 3.64±1.03 
ALP (U/l) 291.04±19.9 485.1±20.1b 374.2±14.1** 328.6±17.2** 309.2±12.2** 
Ca (mg/dl) 7.48±0.37 6.067±0.42a 6.773±0.89 6.955±0.64* 7.058±0.41* 
Chol (mg/dl) 12.03±0.86 7.017±0.87b 9.523±0.53* 9.735±1.55* 11.64±0.57** 
Cr (mg/dl) 0.616±0.02 0.913±0.05 0.765±0.03 0.725±0.03 0.698±0.04 
Glu (mg/dl) 61.95±0.23 50.42±0.41 56.18±0.56 59.78±0.82 60.25±0.69 
P (mg/dl) 9.56±0.69 7.1±0.31b 8.33±0.30* 8.67±0.55* 9.03±0.70** 
SGOT (U/l) 72.62±1.14 110±2.35b 91.31±2.40** 87.67±1.89** 80.14±1.53** 
SGPT (U/l) 4.18±0.25 11.5±0.33b 7.873±0.48 7.953±0.21 6.323±0.59 
Tg (mg/dl) 27.36±0.86 10.2±1.75b 18.78±0.77** 17.89±0.55** 19.45±1.05** 
TP (mg/dl) 4.48±0.11 4.133±0.13 4.307±0.25 4.391±0.14 4.396±0.23 
Data are expressed as mean±SD, N=6 animals per group. Alb albumin, ALP alkaline phosphatase, Ca calcium, Chol total cholesterol, Cr Creatinine, Glu 
glucose, P phosphorus, SGOT serum glutamate oxaloacetate transaminase, SGPT serum glutamate pyruvate transaminase Tg triglyceride, TP total 
protein. a p<0.05, b p<0.001 when compared to control (ANOVA followed by Tukey’s multiple comparison test). *p<0.05, **p<0.001when compared 
to Dex (ANOVA followed by Tukey’s multiple comparison test). 
 
Bone turnover marker assay 
The levels of CTx, TrAcP and b-ALP were highly elevated after two 
months of treatment with dexamethasone indicating induction of 
osteoporosis, while the levels of OC and PINP were highly reduced (fig. 
3). Significant changes were observed in the levels of BTMs after 60 d 
of treatment post osteoporosis induction. It was observed that b-ALP 
(p<0.05) levels reduced significantly and OC (p<0.05) and PINP 
(p<0.05) levels increased significantly when compared with the Dex 
group after treatment with both LNG5 and LNG10. Meanwhile, CTx 
(p<0.05) and TrAcP (p<0.05) levels were reduced significantly in the 
treated groups LNG5 and LNG10 when compared to Dex.  
Micro-CT evaluation 
Micro-CT radiographs obtained using X-radia versa XRM 500 
Micro-CT scanner (X-radia, Zeiss, Germany) are represented in fig. 
4. It clearly demonstrated reduction of trabecular integrity, 
lacunae and decreased thickening of the trabecular wall in Dex 
group after induction of osteoporosis in comparison to control 
group thus indicating that osteoporosis was established. This was 
also evident from the quantitative parameters analysed the 
wherein significant change in BV/TV, Tb. N, Tb. Th and Tb. Sp 
levels (fig. 5) was observed in Dex group in comparison to normal 
rats (p<0.001 for all parameters). 
  
 
Fig. 4: Representative micro-CT images of distal femur head of rat in various treated groups. a) Control b) Dex: dexamethasone sodium, c) 
Dex+ALN: standard treatment alendronate, d) Dex+LNG5: lovastatin nanoemulsion gel (5 mg/ml), e) Dex+LNG10; lovastatin 
nanoemulsion gel (10 mg/ml) 
 
Micro-CT radiographs of the treatment groups (LNG5, LNG10 and ALN 
groups) showed an increase in trabecular integrity, reduction in lacunae 
and improvement in thickening of the trabecular wall. The trabecular 
bone parameters assessed also showed improvements in BV/TV, Tb. N, 
Tb. Th and Tb. Sp levels. BV/TV (p<0.01 for ALN, LNG5 and LNG10), Tb. 
N (p<0.05 for ALN and LNG10), and Tb. Th levels were significantly 
increased (p<0.05) while Tb. Sp was significantly reduced (p<0.01 for 
ALN, LNG5 and LNG10), in comparison with Dex (fig. 5). This effect was 
demonstrated dose-dependently as LNG10 group showed more 
improvements in the BV/TV, Tb. N, Tb. Th and Tb. Sp levels than the 
LNG5 group. BMD also showed significant improvement in the treatment 
groups (p<0.05 for ALN, LNG5 and LNG10) in comparison to Dex. 
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Fig. 5: Comparison of microstructural trabecular bone parameters measured at proximal tibia region of various groups, (a) BV/TV: bone 
volume to tissue volume ratio, (b) Tb. Th: trabecular thickness, (c) Tb. N: trabecular number, (d) Tb. Sp: trabecular separation, (e) BMD: 
bone mineral density. *p<0.05, **p<0.01 versus Dex (calculated using ANOVA followed by Tukey’s multiple comparison test) 
 
Biomechanical strength testing 
The extracted rat tibia bones were subjected to three-point bending 
test and measured peak load, ultimate strength, stiffness, and 
young’s modulus of elasticity of the bones. After osteoporosis 
induction using dexamethasone, significant reductions in peak load 
(p<0.05), stiffness (p<0.05) and ultimate strength (p<0.05) was 
observed in the Dex group when compared to control (fig. 6). The 
treatment groups LNG5 and LNG10 showed significant 
improvements in peak load (p<0.05 for LNG5 and p<0.01 for 
LNG10), stiffness (p<0.05 for LNG5 and p<0.01 for LNG10) and 
ultimate strength (p<0.01 for LNG10). 
 
 
Fig. 6: Biomechanical strength testing of rat tibia representing (a) stiffness (N/mm), (b) peak load (N), (c) ultimate strength (MPa), and 
(d) youngs modulus of elasticity (GPa). Bars represent mean±SD of 6 animals per group, statistically analyzed using ANOVA followed by 
Tukey’s multiple comparison test where *p<0.05 and **p<0.01 versus Dex 
Kaur et al. 




The analysis of various biochemical parameters in blood serum help 
in understanding the trend of biological processes. The serum ALP 
levels were significantly (p<0.001) elevated after dexamethasone 
treatment, thereby indicating the establishment of osteoporosis in 
the rats. This was further supported by a reduction in the serum 
calcium and phosphorus levels. Other parameters viz albumin, 
creatinine, glucose, total protein, SGOT, and SGPT did not show any 
significant changes, thus ruling out the possibility of other effects.  
Biochemical monitoring of bone metabolism i.e. resorption and 
formation can be carried out by analysing various enzymes and 
nonenzymatic peptides derived from the cellular and noncellular 
compartments of bone. These biomolecules released into blood 
circulation are termed as “Bone turnover markers” (BTM). BTMs 
released during different formation phases of active osteoblasts 
represent the bone formation markers such as b-ALP, OC and PINP. 
While the BTMs released during bone resorption process carried by 
osteoclasts form the bone resorption markers such as CTx and 
TRAcP. BTMs respond rapidly to the changes in bone physiology and 
thus are widely utilised for understanding changes in the bone 
during osteoporosis development and treatment [30]. Bone 
formation markers were significantly improved and bone resorption 
markers were significantly reduced after treatment with lovastatin 
NE gel formulations (LNG5 and LNG10) in comparison with Dex 
group. These improvements in the BTMs were almost similar to the 
alendronate treated group thus suggesting that prepared lovastatin 
NE gel preparations could potentially increase bone formation in the 
rats after osteoporosis induction with dexamethasone.  
Micro-CT findings were quite significant in this research as they 
provide substantial data to support the objective of this research 
work. The radiographs showed an increase in trabecular integrity, 
reduction in lacunae, and improvement in thickening of the 
trabecular wall after treatment with NE gel in comparison with Dex 
group. The trabecular bone parameters BV/TV, Tb. N, Tb. Th and Tb. 
Sp levels of Dex+LNG5 and Dex+LNG10 groups were significantly 
improved in comparison with the Dex group, thus indicating the 
efficacy of prepared NE gel formulations of lovastatin. Moreover, the 
improvements were more significant in LNG10 group than LNG5 
group, thus indicating a dose-dependent effect. Similar findings were 
reported by us in the femur bone as well [22]. 
The biomechanical strength testing was carried out to study the 
load-bearing capacity of the tibia bones before and after treatment 
with lovastatin NE gel. Dex+LNG5 and Dex+LNG10 groups showed 
improvement in peak load, ultimate stress, stiffness and young’s 
modulus of elasticity in comparison with osteoporosis group (Dex), 
thus indicating an increase in the load-bearing capacity of the rat 
tibia. The significant improvement in biomechanical strength testing 
parameters indicates the effectiveness of the lovastatin NE gel 
formulation in osteoporosis. 
CONCLUSION 
Overall, the transdermal NE gel of lovastatin showed positive effects 
on the dexamethasone-induced osteoporotic rat tibia bones. 
Moreover, significant improvements were seen dose-dependently. 
Thus the present animal study suggests it could be an alternative 
therapy for osteoporosis, however further clinical studies should be 
intervened to explore its full potential. 
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